Cargando…

How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022

From January 2020 to December 2022, there was a total of 8,872,955 confirmed COVID-19 cases in Taiwan. In addition, a total of 15,253 COVID-19 related deaths were reported. During these three years, the government and health authority did many efforts to response this pandemic. In the early pandemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Chih-Cheng, Lee, Ping-Ing, Hsueh, Po-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079311/
https://www.ncbi.nlm.nih.gov/pubmed/37061349
http://dx.doi.org/10.1016/j.jmii.2023.04.001
_version_ 1785020701211623424
author Lai, Chih-Cheng
Lee, Ping-Ing
Hsueh, Po-Ren
author_facet Lai, Chih-Cheng
Lee, Ping-Ing
Hsueh, Po-Ren
author_sort Lai, Chih-Cheng
collection PubMed
description From January 2020 to December 2022, there was a total of 8,872,955 confirmed COVID-19 cases in Taiwan. In addition, a total of 15,253 COVID-19 related deaths were reported. During these three years, the government and health authority did many efforts to response this pandemic. In the early pandemic, Taiwan Central Epidemic Command Center was established in the early 2020 to organize associated resource, develop effective policy and implement strict intervention. In response to COVID-19 pandemic, many infection control policy and interventions, including universal mask wearing with increasing production of face mask, hand hygiene, border control, introduce of digital technology incorporating big data, quarantine of COVID-19 cases, travel and gathering restriction, were implemented. In the meanwhile, two COVID-19 vaccines, namely MVC-COV1901 and UB-612, have been developed under the support of government. Furthermore, MVC-COV1901 was taken into clinical practice after received emergency use approval. In addition, two traditional Chinese medicines, including NRICM101 and NRICM102 showed their promising effect against SARS-CoV-2 infection and were recommended as potential therapeutic options for COVID-19. During the pandemic, the nonpharmacologic intervention help reduce many infectious diseases, especially for airborne/droplet-transmitted diseases. However, COVID-19 exhibited some adverse impacts on the healthcare systems, such as emergency medical service on out of hospital cardiac arrest, cancer screening, HIV screening and prevention services, and public health, namely the psychosocial status of healthcare workers. Although the outbreak of SARS-CoV-2 infections may gradually subsided, we should keep monitoring its associated impact and appropriately response to this pandemic.
format Online
Article
Text
id pubmed-10079311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
record_format MEDLINE/PubMed
spelling pubmed-100793112023-04-07 How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022 Lai, Chih-Cheng Lee, Ping-Ing Hsueh, Po-Ren J Microbiol Immunol Infect Review Article From January 2020 to December 2022, there was a total of 8,872,955 confirmed COVID-19 cases in Taiwan. In addition, a total of 15,253 COVID-19 related deaths were reported. During these three years, the government and health authority did many efforts to response this pandemic. In the early pandemic, Taiwan Central Epidemic Command Center was established in the early 2020 to organize associated resource, develop effective policy and implement strict intervention. In response to COVID-19 pandemic, many infection control policy and interventions, including universal mask wearing with increasing production of face mask, hand hygiene, border control, introduce of digital technology incorporating big data, quarantine of COVID-19 cases, travel and gathering restriction, were implemented. In the meanwhile, two COVID-19 vaccines, namely MVC-COV1901 and UB-612, have been developed under the support of government. Furthermore, MVC-COV1901 was taken into clinical practice after received emergency use approval. In addition, two traditional Chinese medicines, including NRICM101 and NRICM102 showed their promising effect against SARS-CoV-2 infection and were recommended as potential therapeutic options for COVID-19. During the pandemic, the nonpharmacologic intervention help reduce many infectious diseases, especially for airborne/droplet-transmitted diseases. However, COVID-19 exhibited some adverse impacts on the healthcare systems, such as emergency medical service on out of hospital cardiac arrest, cancer screening, HIV screening and prevention services, and public health, namely the psychosocial status of healthcare workers. Although the outbreak of SARS-CoV-2 infections may gradually subsided, we should keep monitoring its associated impact and appropriately response to this pandemic. Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2023-06 2023-04-06 /pmc/articles/PMC10079311/ /pubmed/37061349 http://dx.doi.org/10.1016/j.jmii.2023.04.001 Text en © 2023 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Lai, Chih-Cheng
Lee, Ping-Ing
Hsueh, Po-Ren
How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
title How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
title_full How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
title_fullStr How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
title_full_unstemmed How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
title_short How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
title_sort how taiwan has responded to covid-19 and how covid-19 has affected taiwan, 2020–2022
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079311/
https://www.ncbi.nlm.nih.gov/pubmed/37061349
http://dx.doi.org/10.1016/j.jmii.2023.04.001
work_keys_str_mv AT laichihcheng howtaiwanhasrespondedtocovid19andhowcovid19hasaffectedtaiwan20202022
AT leepinging howtaiwanhasrespondedtocovid19andhowcovid19hasaffectedtaiwan20202022
AT hsuehporen howtaiwanhasrespondedtocovid19andhowcovid19hasaffectedtaiwan20202022